CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
The chart shows the growth of an initial investment of $10,000 in The Cooper Companies, Inc. Common Stock, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
The Cooper Companies, Inc. Common Stock (COO) has returned -14.52% so far this year and -4.80% over the past 12 months. Looking at the last ten years, COO has achieved an annualized return of 5.87%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of The Cooper Companies, Inc. Common Stock (COO) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.86% | 2.99% | -14.46% | -2.31% | ||||||||
| 2025 | 4.30% | -5.12% | -7.28% | -2.99% | -17.65% | 4.08% | -0.44% | -4.40% | 3.28% | 3.31% | 11.89% | 5.65% |
| 2024 | -0.28% | -0.08% | -0.57% | -11.86% | 5.93% | -7.45% | 6.91% | 13.31% | 5.09% | -4.70% | -0.44% | -11.72% |
| 2023 | 4.50% | -6.54% | 14.78% | 2.65% | -2.30% | 3.35% | 2.79% | -4.58% | -14.68% | -1.08% | 7.98% | 12.43% |
| 2022 | -6.97% | 3.05% | 2.35% | -13.72% | -3.16% | -11.13% | 4.33% | -11.52% | -7.74% | 1.89% | 14.47% | 3.03% |
| 2021 | -0.26% | 5.08% | -0.95% | 7.12% | -4.68% | 0.18% | 6.31% | 6.60% | -7.86% | 0.74% | -9.76% | 9.76% |
| 2020 | 7.32% | -6.97% | -15.96% | 6.66% | 11.70% | -10.60% | 0.00% | 10.56% | 7.03% | -6.15% | 3.52% | 7.37% |
| 2019 | 10.82% | 1.44% | 3.13% | -2.71% | 2.77% | 12.82% | -0.58% | -8.03% | -3.82% | -2.20% | 7.08% | 2.48% |
| 2018 | 12.28% | -5.27% | -0.64% | 0.31% | -1.10% | 3.44% | 11.53% | -1.30% | 8.35% | -6.85% | 7.37% | -9.08% |
| 2017 | 5.08% | 8.23% | -0.06% | 0.28% | 8.94% | 9.22% | 1.86% | 2.33% | -3.22% | 0.99% | 0.27% | -9.82% |
| 2016 | -0.32% | 6.57% | 5.32% | 5.64% | 1.93% | -3.31% | -0.90% | -6.04% | 6.19% |
The charts below present risk-adjusted performance metrics for The Cooper Companies, Inc. Common Stock (COO) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of COO compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current The Cooper Companies, Inc. Common Stock volatility is 1.73%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 12.39B | 12.32B | 11.66B | 11.49B | 9.61B | 6.74B | 6.27B | 6.11B | 4.86B | 4.48B | 4.46B | 4.46B | 3.14B | 2.94B | 2.62B |
| Equity Attributable To Parent (USD) | 8.24B | 8.08B | 7.55B | 7.17B | 6.94B | 3.82B | 3.63B | 3.31B | 3.18B | 2.70B | 2.67B | 2.57B | 2.40B | 2.19B | 1.94B |
| Equity Attributable To Noncontrolling Interest (USD) | 200.00K | 200.00K | 200.00K | 200.00K | 200.00K | 200.00K | 200.00K | 200.00K | 100.00K | 168.00K | 6.40M | 18.56M | 18.96M | 20.41M | - |
| Equity (USD) | 8.24B | 8.08B | 7.55B | 7.17B | 6.94B | 3.82B | 3.63B | 3.31B | 3.18B | 2.70B | 2.67B | 2.59B | 2.42B | 2.21B | 1.94B |
| Noncurrent Liabilities (USD) | 3.04B | 3.21B | 3.14B | 3.04B | 1.93B | 1.91B | 1.54B | 2.27B | 1.29B | 1.24B | 1.22B | 1.43B | 392.51M | 465.67M | 419.82M |
| Other Current Liabilities (USD) | 601.80M | 587.50M | 532.30M | 879.30M | 422.00M | 709.40M | 855.80M | 296.10M | 169.90M | 351.35M | 384.89M | 257.93M | 149.67M | 118.06M | 156.66M |
| Wages (USD) | 210.60M | 174.80M | 174.80M | 152.10M | 148.70M | 119.00M | 104.70M | 94.00M | 84.10M | 77.72M | 67.37M | 67.90M | 63.41M | 59.44M | 48.79M |
| Accounts Payable (USD) | 300.40M | 260.50M | 261.90M | 248.80M | 161.40M | 176.00M | 150.10M | 146.40M | 142.10M | 107.39M | 116.91M | 116.35M | 108.17M | 85.06M | 61.76M |
| Current Liabilities (USD) | 1.11B | 1.02B | 969.00M | 1.28B | 732.10M | 1.00B | 1.11B | 536.50M | 396.10M | 536.46M | 569.17M | 442.18M | 321.25M | 262.55M | 267.21M |
| Liabilities (USD) | 4.16B | 4.23B | 4.11B | 4.32B | 2.66B | 2.91B | 2.65B | 2.81B | 1.68B | 1.78B | 1.79B | 1.87B | 713.77M | 728.23M | 687.03M |
| Other Non-current Assets (USD) | 6.62B | 6.71B | 6.61B | 6.66B | 5.52B | 2.89B | 2.57B | 2.52B | 2.49B | 2.22B | 2.24B | 2.28B | 1.45B | 1.43B | 1.35B |
| Intangible Assets (USD) | 1.59B | 1.79B | 1.71B | 1.89B | 1.27B | 1.29B | 1.41B | 1.52B | 504.70M | 441.09M | 411.10M | 453.61M | 198.77M | 214.78M | 128.34M |
| Fixed Assets (USD) | 2.08B | 1.86B | 1.63B | 1.41B | 1.35B | 1.28B | 1.13B | 976.00M | 910.10M | 877.67M | 967.10M | 937.33M | 739.87M | 640.26M | 609.21M |
| Noncurrent Assets (USD) | 10.29B | 10.36B | 9.95B | 9.96B | 8.14B | 5.46B | 5.11B | 5.02B | 3.91B | 3.54B | 3.62B | 3.67B | 2.39B | 2.28B | 2.08B |
| Other Current Assets (USD) | 1.26B | 1.15B | 969.30M | 904.90M | 879.70M | 703.80M | 656.50M | 622.10M | 499.10M | 516.76M | 422.13M | 410.14M | 408.32M | 337.66M | 286.76M |
| Inventory (USD) | 846.00M | 802.70M | 735.60M | 628.70M | 585.60M | 570.40M | 506.90M | 468.80M | 454.10M | 417.70M | 419.69M | 381.47M | 338.92M | 320.20M | 253.58M |
| Current Assets (USD) | 2.11B | 1.95B | 1.70B | 1.53B | 1.47B | 1.27B | 1.16B | 1.09B | 953.20M | 934.46M | 841.82M | 791.62M | 747.24M | 657.86M | 540.35M |
| Assets (USD) | 12.39B | 12.32B | 11.66B | 11.49B | 9.61B | 6.74B | 6.27B | 6.11B | 4.86B | 4.48B | 4.46B | 4.46B | 3.14B | 2.94B | 2.62B |
As the stock market rotates away from mega-cap growth stocks, three undervalued companies offer compelling opportunities: Keurig Dr Pepper trades at a discount to beverage peers with attractive dividend yields; Cooper Companies benefits from healthcare sector resilience with strong EPS growth prospects; and Matador Resources capitalizes on the energy sector's 21% YTD surge with robust revenue growth and cash flow generation.
The global ART market is projected to grow from $30.1 billion in 2024 to $60.7 billion by 2033 at a CAGR of 8.1%, driven by rising infertility prevalence, delayed parenthood, and expanding employer-sponsored fertility benefits. IVF dominates with 90% market share, while Europe leads with 35.80% of the global market. Over 450 Fortune 500 companies now offer fertility benefits, with specialized platforms facilitating over 500,000 virtual consultations in 2024.
The global ART market is projected to grow from $30.1 billion in 2024 to $60.7 billion by 2033 at a CAGR of 8.1%, driven by rising infertility prevalence, delayed parenthood, and expanding employer-sponsored fertility benefits. IVF dominates with 90% market share, while Europe leads with 35.80% of the global market. Over 450 Fortune 500 companies now offer fertility benefits, with specialized platforms facilitating over 500,000 virtual consultations in 2024.
The global contact lens market is projected to grow from USD 18.88 billion in 2025 to USD 26.64 billion by 2033, expanding at a CAGR of 4.42%. Growth is driven by rising myopia prevalence, increasing adoption of disposable lenses, and technological advancements in silicone hydrogel materials. However, risks from eye infections and user discomfort may hinder expansion. The U.S. market leads North America with expected growth to USD 6.83 billion by 2033.
A Georgia federal judge denied Teva Pharmaceutical's request to delay the first trial in approximately 3,800 lawsuits alleging its Paragard copper IUD can fracture during removal. The trial is scheduled to proceed on January 20. The judge previously expressed concerns about Teva's five-year delay in complying with an FDA mandate to update warning labels and rejected the company's preemption defense arguments.
CooperCompanies announced the appointment of Walt M Rosebrough, Jr., former CEO of STERIS, as an independent director effective January 3, 2026, following a cooperation agreement with activist investor Browning West. Rosebrough will join the Corporate Governance & Nominating Committee with consideration for Board Chair by end of 2026. The company also committed to appointing a new independent director with medical technology experience.
Cooper Companies reported strong Q4 earnings, beating expectations, and announced a portfolio review to unlock long-term value. The company expects positive organic growth and raised fiscal 2026 guidance.
U.S. stock futures fluctuated on Friday as investors anticipate the September PCE price index. Job cuts fell 53% month-over-month in November, and markets expect a potential Federal Reserve interest rate cut in December.
Browning West, a major shareholder, criticized Cooper Companies for underperformance, weak governance, and misaligned capital allocation strategies across its CooperVision and CooperSurgical divisions.
Alcon reported Q3 sales of $2.59 billion, slightly missing consensus but beating earnings expectations. The company saw strong growth in surgical and vision care segments, with promising new technologies like Unity VCS and PanOptix Pro.
